Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NPC intracellular cholesterol transporter 2 (NPC2) is a small soluble glycoprotein localized predominantly within lysosomes, where it binds and transfers cholesterol and certain other sterols. NPC2 acts as a cholesterol shuttle, interacting with membranes—particularly through its hydrophobic knob domain and in cooperation with the lysosomal membrane protein NPC1 and the phospholipid LBPA—to facilitate the movement of cholesterol from lysosomes to other cellular compartments[1][2][3][4][5][7]. Deficiency or dysfunction of NPC2 leads to abnormal cholesterol accumulation in late endosomes and lysosomes, resulting in Niemann-Pick disease type C2, a severe neurodegenerative lysosomal storage disorder characterized by lipid accumulation, organ dysfunction, and premature death[1][2][4][8]. In addition to its essential roles in lipid metabolism, NPC2 also influences antigen presentation and immune cell development via its effects on lipid transfer and NKT cell selection[2]. Plasma NPC2 protein levels may serve as a biomarker for Niemann-Pick C diagnosis and monitoring[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NPC intracellular cholesterol transporter 2 (NPC2).